Nov 04, 2022 / 12:45PM GMT
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the AASLD 2022 Clinical Data Presentation. (Operator Instructions) At this time, I would like to turn the conference over to Ms. Lisa Caperelli, Ma'am, please begin.
Lisa M. Caperelli - Arbutus Biopharma Corporation - VP of IR
Thank you, Howard. Good morning, everyone, and thank you for joining our webcast. As a reminder, we will be presenting slides on this webcast. You can access the slides via the Investors section of our website at arbutusbio.com.
With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.
Bill will begin with a quick summary of the AASLD liver meeting presentations. Gaston will then walk you through the highlights of the AB-729 clinical data that will be presented at AASLD on Monday. And Mike will then share preclinical AB-101 data. All this data was described in today's press release. We will then open the call for
Arbutus Biopharma Corp AASLD Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot